drugset / Trial / NCT00596271

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

NCT00596271

Phase 3 Completed 192 enrolled Valneva Austria GmbH
RandomizedParallel-groupSingle-blindPrevention

Summary

The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440

Timeline

Start
2005-09
Primary completion
2006-07
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Havrix Vaccine
Comparator IC51 Vaccine 6 ug Intramuscular

Indications